StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Protara Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$31.49M. For fiscal 2016 it was -$28.58M. The highest annual figure on record is -$7.10M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2016Dec 31, 2016-$28.58M–
FY2015Dec 31, 2015-$20.81M–
FY2014Dec 31, 2014-$7.55M–
FY2013Dec 31, 2013-$7.10M–
FY2012Dec 31, 2012-$7.94M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2017Sep 30, 2017-$12.27M–
Q2 FY2017Jun 30, 2017-$5.95M–
Q1 FY2017Mar 31, 2017-$6.44M–
Q4 FY2016Dec 31, 2016-$6.83M–
Q3 FY2016Sep 30, 2016-$7.13M–

More Protara Therapeutics figures

See a number that looks wrong?